- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
22 result(s) found for: Minerals.
Displaying page 1 of 2.
EudraCT Number: 2006-002273-41 | Sponsor Protocol Number: OPHT-110106 | Start Date*: 2006-06-12 |
Sponsor Name:Medical University of Vienna; Clinical Pharmacology | ||
Full Title: Effect of antioxidants on ocular blood flow, endothelial function, and cytokine levels in LPS induced inflammatory model in humans. | ||
Medical condition: only healthy volunteers are involved | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010138-22 | Sponsor Protocol Number: OPHT-101108 | Start Date*: 2009-04-02 |
Sponsor Name:Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Effect of antioxidants on oxygen induced vasoconstriction in LPS induced inflammatory model in humans | ||
Medical condition: Healthy volunteers are included | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004885-33 | Sponsor Protocol Number: 04/4 | Start Date*: 2008-07-29 |
Sponsor Name:Bio Minerals n.v. | ||
Full Title: Topical treatment of hand osteoarthritis with glucosamine cream. | ||
Medical condition: osteoarthritis of the hands | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002940-86 | Sponsor Protocol Number: SELLIFA-02 | Start Date*: 2007-08-24 | |||||||||||
Sponsor Name:Cliniques Universitaires Saint-Luc – Université catholique de Louvain | |||||||||||||
Full Title: Sepsis, Endothelial function, and Lipids in critically ill patients with Liver Failure (SELLIFA). Nutritional sub-study : Randomized controlled trial comparing the tolerance on lipid metabolism and... | |||||||||||||
Medical condition: Liver failure, Liver cirrhosis, critical illness, total nutritional support | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023311-34 | Sponsor Protocol Number: CPA 368-10 | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol... | |||||||||||||
Medical condition: healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004677-17 | Sponsor Protocol Number: 141022 | Start Date*: 2016-02-29 | ||||||||||||||||
Sponsor Name:Kvinnokliniken, Universitetssjukhuset i Linköping, Landstinget i Östergötland | ||||||||||||||||||
Full Title: Contraception after gastric bypass - part 4 How does gastric bypass affect the pharmacocinetics of oral levonorgestrel? | ||||||||||||||||||
Medical condition: We want to investigate if the pharmacocinetics of levonorgestrel differs in women who have had bariatric surgery compared to women who have not. Measures of serum concentrations of levonorgestrel w... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005797-58 | Sponsor Protocol Number: 465 | Start Date*: 2013-04-19 | ||||||||||||||||
Sponsor Name:Kvinnokliniken, Universitetessjukhuset i Linköping, landstinget i Östergötland | ||||||||||||||||||
Full Title: Contraception after gastric bypass - part three How does gastric bypass affect the pharmacocinetics of oral desogestrel? | ||||||||||||||||||
Medical condition: We want to investigate how the pharmacocinetics changes for Cerazette in 14 fertile obese women after, compared to before, bariatric surgery in forms of gastric by pass. Mesures of serum concetrati... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000715-29 | Sponsor Protocol Number: SR-SJI/AM | Start Date*: 2007-04-16 | ||||||||||||||||
Sponsor Name:University Hospitals of Leicester - Research & Development | ||||||||||||||||||
Full Title: Serum and urinary strontium levels and possible interference with measurement of other minerals in subjects taking Strontium ranelate (Protelos) for osteoporosis. | ||||||||||||||||||
Medical condition: Osteoporosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001439-30 | Sponsor Protocol Number: ALS-Gd64/001 | Start Date*: 2013-03-22 |
Sponsor Name:Navitas Life Sciences GmbH | ||
Full Title: Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history. | ||
Medical condition: Retention of gadolinium/traces of metals/minerals to be determined in bone/skin specimens and evaluation of signs of nephrogenic systemic fibrosis in skin. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Prematurely Ended) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000373-21 | Sponsor Protocol Number: IRX-22015A | Start Date*: 2016-10-27 | |||||||||||
Sponsor Name:IRX Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity | |||||||||||||
Medical condition: Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004135-36 | Sponsor Protocol Number: WTX101-301 | Start Date*: 2018-03-23 |
Sponsor Name:Wilson Therapeutics AB | ||
Full Title: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older... | ||
Medical condition: Wilson Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) AT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) PT (Completed) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-000881-22 | Sponsor Protocol Number: M10-336 | Start Date*: 2008-07-17 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... | |||||||||||||
Medical condition: Treatment-naïve, HIV-1 infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002233-12 | Sponsor Protocol Number: CERL080ADE08 | Start Date*: 2006-04-13 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid | |||||||||||||
Medical condition: patients with autoimmune diseases treated with MPA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000315-91 | Sponsor Protocol Number: RG_18-236 | Start Date*: 2019-09-09 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: The pAToMiUM Trial: pilot trial of Antioxidant Therapy of Men in Unexplained Miscarriage | |||||||||||||
Medical condition: Unexplained miscarriage and how this may relate to the quality of the sperm DNA at conception, with particular emphasis on chromatin structure and DNA fragmentation and whether this may be improved... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002234-35 | Sponsor Protocol Number: CERL080ADE09 | Start Date*: 2006-10-05 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients | |||||||||||||
Medical condition: patients who have received a liver transplant treated with mycophenolic acid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000861-36 | Sponsor Protocol Number: ENS/007612 | Start Date*: 2013-05-17 | |||||||||||
Sponsor Name:Ensinger Mineral-Heilquellen GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of „Ensinger Schiller Quelle Heilwasser“ on improvement of bowel function | |||||||||||||
Medical condition: - Functional constipation according to the ROME III criteria - The subjects have bowel movements 2 - 4 days/week | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001430-32 | Sponsor Protocol Number: M05-730 | Start Date*: 2005-11-18 |
Sponsor Name:Abbott GmbH & Co. KG | ||
Full Title: A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Completed) GR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000748-14 | Sponsor Protocol Number: M06-802 | Start Date*: 2006-08-14 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... | |||||||||||||
Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004946-41 | Sponsor Protocol Number: SP-PP18 | Start Date*: 2019-09-12 |
Sponsor Name:Dr. Virgilio P. Carnielli, | ||
Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial | ||
Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001104-41 | Sponsor Protocol Number: ALXN1840-WD-204 | Start Date*: 2020-07-22 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840 | |||||||||||||
Medical condition: Wilson Disease (WD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
